Research progress of radiotherapy and CDK4/6 inhibitors in metastatic breast cancer
10.3760/cma.j.cn371439-20201222-00121
- VernacularTitle:放疗联合CDK4/6抑制剂治疗转移性乳腺癌的进展
- Author:
Yiting YANG
1
;
Xiaoting XU
Author Information
1. 苏州大学附属第一医院放疗科 215006
- Keywords:
Breast neoplasms;
Cyclin-dependent kinase inhibitor proteins;
Radiotherapy
- From:
Journal of International Oncology
2021;48(10):618-621
- CountryChina
- Language:Chinese
-
Abstract:
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a new class of molecular targeted drugs, which can enhance radiotherapy sensitivity by anti angiogenesis, inhibiting DNA damage repair and inhibiting mammalian target of rapamycin signal transduction. Existing clinical trials have confirmed that radiotherapy combined with CDK4/6 inhibitors can effectively control the local symptoms of breast cancer metastases and prolong progression-free survival. Compared with CDK4/6 inhibitors alone, the combination with radiotherapy does not significantly increase the incidence and severity of adverse reactions. However, there are also reports about severe adverse reactions of normal tissue happened in the radiation field in individual cases of combined treatment, and its efficacy and safety need to be clarified by more basic and clinical observational researches.
